Lumexa Imaging Holdings reported second quarter 2026 financial results and updated its full-year outlook. Consolidated revenues reached $264.2 million, a 5.1% increase from the prior year period. The company returned to profitability with net income of $2.7 million compared to a net loss of $7.2 million in the previous quarter. Adjusted EBITDA was $56.4 million, maintaining a 21.4% margin. GAAP EPS was $0.03 and Adjusted EPS was $0.20 per share. The company reiterated full-year revenue guidance of $1.045 billion to $1.097 billion and narrowed its Adjusted EBITDA range to $235 million–$241 million, with a midpoint of $238 million unchanged from prior expectations. Lumexa Imaging operates in the healthcare industry as a nationwide provider of outpatient medical imaging services.

On June 30, 2026, Lumexa Imaging Holdings, Inc. through its subsidiaries entered into an amended Credit Agreement with Barclays Bank PLC as administrative agent. The agreement establishes a secured term loan facility of approximately $823 million maturing in December 2032 and a $250 million secured revolving line of credit maturing in December 2030. Both facilities carry interest rates of either SOFR plus 2.50% or the Prime Rate plus 1.50%. The agreement includes restrictive covenants on debt, dividends, and distributions, as well as a financial covenant requiring a consolidated net leverage ratio not exceeding 7.50 to 1 if revolving credit exposure exceeds 40% of the facility. The company operates in the healthcare imaging industry providing diagnostic imaging services.